

Corporate Overview

ORE Pharmaceuticals at a glance

Ore Pharmaceuticals is a leading drug repositioning and development company. We use our Indication-Seeking Program to identify new uses for clinical-stage drug candidates that have stalled or failed for reasons other than safety.

A THIRD-WAY TO ENRICH THE PIPELINE

The two conventional methods for filling pharma's pipeline—advancing internally developed candidates and in-licensing externally-generated ones—are no longer yielding robust compound portfolios. Drug repositioning offers pharmaceutical companies a third way to expand their drug development pipelines and is also the primary process through which we are building our own pipeline.

Our goal is to supply the pharmaceutical industry's demand for development-stage drug compounds to enrich pipelines. We do this by identifying new uses for stalled or failed compounds provided by pharmaceutical partners and for compounds acquired from the public domain.

PATHS TO EXTRACTING VALUE

Ore Pharmaceuticals is currently partnering with Pfizer, Roche, Organon, Eli Lilly, Abbott, H. Lundbeck, Merck Serono and Solvay, to seek new indications for stalled or failed compounds.

In addition to working with pharmaceutical partners to fill their pipelines, we are also building our own pipeline.

The initial compound in our own drug development pipeline is GL1001, a clinical-stage small molecule drug candidate that was originally intended to treat obesity. Using our Indication-Seeking Program, we discovered potential new therapeutic applications for GL1001 as a treatment for inflammatory bowel disease or IBD (ulcerative colitis and Crohn's disease), non-ulcer dyspepsia, gastric ulcers, esophagitis and chronic pancreatitis. We then validated the IBD application through *in vivo* testing. Based on extensive preclinical safety testing, we have found that GL1001 has a favorable safety profile. In addition, no safety concerns were noted in a single escalating dose clinical study conducted in humans for the drug's original purpose. We are currently seeking an out-licensing partner for this compound.

OUR BUSINESS MODEL

Ore Pharmaceuticals' business model is based on extracting economic value from dead drugs. Our goal is to produce income in two ways: by monetizing compounds such as GL1001 from our own drug development pipeline through out-licensing or various forms of collaboration; and by earning milestones and royalties from our drug repositioning partners who put their compounds back into their own development pipelines for uses we have identified.

INDICATION-SEEKING PROGRAM AND PARTNERS

We believe that no single technology is adequate to assess the effect of a compound across complex biological processes. That's why our expert team of pharmaceutical scientists and technology specialists

uses a proprietary integrative multi-technology platform to systematically evaluate compounds against more than 400 diseases. We use *In Vivo* Imaging, Multiplex Bioanalytics, Molecular & Cellular Pharmacology, and *In Silico* Biology assessments of a compound to develop and cross-confirm alternative indication hypotheses.

This proprietary multi-pronged approach lets us work quickly and efficiently. But most importantly, it results in repositioned drugs that are analyzed in-depth—providing a solid scientific rationale for returning compounds to clinical development.

So far, we have initiated evaluation of more than 100 partner-provided compounds and proposed alternative indications for approximately one third of the compounds for which the full evaluations have been completed.

DEVELOPING OUR OWN PIPELINE

Ore Pharmaceuticals' Indication-Seeking Program is the discovery engine for drug candidates entering our drug development pipeline. There may be instances when our pharmaceutical partners decide not to develop a compound we identify as having new uses. This gives us the opportunity to acquire high-quality, late-stage compounds such as GL1001. We also acquire compounds through our own analysis of drugs in the public domain. Our objective is to out-license select drug repositioned compounds.

Management Team

Our senior team consists of proven managers with industry expertise and highly qualified scientists, all of whom are dedicated to creating shareholder value.

Charles L. Dimmler, III
Chief Executive Officer & President

Philip L. Rohrer, Jr.
Chief Financial Officer

Thomas Barnes, Ph.D.
Senior Vice President,
Drug Repositioning Discovery

Stephen Donahue, M.D.
Senior Vice President,
Clinical Development

F. Dudley Staples, Jr., J.D.
Senior Vice President;
Secretary;
General Counsel;

Larry Tiffany
Interim Head,
Commercial Operations

Deborah Barbara
Vice President,
Business Development & Licensing

John Herrmann, III, J.D.
Vice President,
Strategic Alliances & Licensing;
Deputy General Counsel

Headquarters

Ore Pharmaceuticals Inc.
610 Professional Drive
Gaithersburg, MD 20879
240.361.4400

Cambridge Office

Ore Pharmaceuticals Inc.
38 Sidney Street, 2nd Floor
Cambridge, MA 02139
617.649.2001

orepharma.com
1.877.ORE.PHRM